JHVEPhoto/iStock Editorial via Getty Images The merger agreement between Taro Pharmaceutical ( NYSE: TARO ) and Sun Pharma, was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, the companies reported on Thursday. Upon completion of the merger, currently expected to close in approximately 35 days, Taro ( TARO ) will become a privately held company wholly owned by Sun Pharma and soon after its shares will be de-listed from the NYSE. Under the deal, Sun will pay $43 per share for all the outstanding ordinary Taro shares ( TARO ) that it doesn’t already own.
Source: Press Release More on Taro Pharmaceutical Estée Lauder, Reckitt, Taro Pharma fall amid cancer risk in acne treatments Seeking Alpha’s Quant Rating on Taro Pharmaceutical Financial information for Taro Pharmaceutical.
